Skip to main content
IXICO PLC logo

IXICO PLC — Investor Relations & Filings

Ticker · IXI ISIN · GB00BFXR4C20 LEI · 2138005M1F59O6HWSA97 IL Professional, scientific and technical activities
Open in API
Filings indexed 354 across all filing types
Latest filing 2018-05-14 Regulatory Filings
Country GB United Kingdom
Listing IL IXI

About IXICO PLC

https://www.ixico.com/

IXICO PLC is a clinical research and data analytics company specializing in neuroscience. It provides neuroimaging and digital biomarker analytics to biopharmaceutical firms conducting clinical trials for neurological disorders. The company utilizes its proprietary, AI-driven technology platform to manage and analyze complex imaging and digital health data. This platform deploys disease-specific algorithms to generate reliable clinical data and precision insights, aiming to accelerate research and development decision-making, de-risk clinical studies, and support the advancement of new therapies for conditions such as Alzheimer's and Huntington's disease.

Recent filings

Filing Released Lang Actions
New contract with top 10 pharmaceutical company
Regulatory Filings Classification · 1% confidence The document is identified by the presence of an 'RNS Number' and the closing statement indicating the information is provided by 'RNS The company news service from the London Stock Exchange'. The content announces a specific business event: signing a new contract worth £1.0m for clinical trials services. This is a material, non-periodic business update that is typically disseminated via regulatory news services. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific corporate action like a dividend (DIV) or share transaction (POS), the most appropriate general category for a standard regulatory announcement disseminated via RNS is 'Regulatory Filings' (RNS). The document length (4038 chars) is substantial enough to be the announcement itself, not just a brief notice of publication.
2018-05-14 English
Expansion of two biopharmaceutical contracts
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces an expansion of existing contracts, increasing their value by £0.5m, which is a material business update but not a full financial report (like 10-K or IR), a dividend announcement, or a management change. Since it is a general, material announcement disseminated through the Regulatory News Service (RNS) system and does not fit precisely into the other specific categories (like ER, CAP, or DIV), the most appropriate classification is the general regulatory filing category.
2018-05-10 English
Notice of Interim Results
Report Publication Announcement Classification · 1% confidence The document is very short (2050 characters) and explicitly states its purpose in the title: "Notice of Interim Results". It informs the reader that the company "will announce its interim results for the six months ending 31 March 2018 on Wednesday 23 May 2018." This structure—announcing the future publication date of a report rather than containing the report itself—fits the definition of a Report Publication Announcement (RPA). The presence of the RNS Number further confirms it is a regulatory announcement about a forthcoming report.
2018-05-03 English
Placing to raise ?5.5 million
Regulatory Filings Classification · 1% confidence The document is an RNS announcement (indicated by 'RNS Number : 9415M' and the mention of 'Results of General Meeting announced via RNS'). The content details a proposed fundraising via a placing (£5.5 million), which is conditional on shareholder approval at a General Meeting. It also mentions the announcement of a circular to be posted to shareholders today and provides an expected timetable for the General Meeting. Since the document is an announcement regarding a corporate action (fundraising and related General Meeting) that requires shareholder approval, and it explicitly mentions the associated circular and timetable, it strongly relates to the process leading up to a shareholder vote. The key elements are the 'Notice of General Meeting' and the associated capital raising. This structure is typical of documents related to shareholder meetings and proposals, which often fall under Proxy Solicitation/Information Statements (PSI) or, given the context of a General Meeting being called, potentially AGM-R if it were the AGM itself, but here it is a specific corporate action requiring a vote. However, the primary action announced is the capital raise conditional on a General Meeting, and the document itself is a formal regulatory announcement (RNS). Since it calls a General Meeting and details resolutions (implied by the timetable for proxy forms and results), it is highly related to shareholder voting materials. Given the options, 'DEF 14A' is for remuneration, 'AGM-R' is for the meeting materials themselves, and 'PSI' is for proxy solicitation. Because it announces the meeting and the resolutions needed for the placing, it functions as a key piece of information soliciting shareholder action/vote, making 'PSI' (Proxy Solicitation & Information Statement) a strong candidate, or 'CAP' for the financing aspect. However, the document explicitly calls a General Meeting and details the resolutions required for the placing, which is a core function of a proxy/information statement sent to solicit votes. Furthermore, the document is clearly a regulatory announcement (RNS). Since it details the mechanics and timing of a General Meeting required for a capital raise, it fits best under the category dealing with shareholder voting materials. Given the structure, it is a formal announcement of corporate actions requiring a vote, which aligns closely with the purpose of a Proxy Statement. I will classify it as PSI due to the focus on the General Meeting and associated resolutions, although RNS is also applicable as the distribution method.
2018-05-03 English
Agreement
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content describes a specific business event: the expansion of an existing contract with a pharmaceutical company, detailing the increase in contract value and duration. This is a material business update that does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). Since it is a general, material announcement distributed through the official regulatory news service (RNS), and it is not a specific type like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS.
2018-04-04 English
New contract in progressive supranuclear palsy
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated January 30, 2018. The content announces a specific business event: signing a new $2.7m contract for clinical trial services related to progressive supranuclear palsy (PSP) with a global pharmaceutical company. This is a material, non-financial announcement made via the Regulatory News Service (RNS) system of the London Stock Exchange. Since it is a specific business update that doesn't fit into categories like Director's Dealing (DIRS), Dividend (DIV), or Earnings Release (ER), and it is a direct announcement rather than a report itself, the most appropriate classification is the general regulatory announcement category, RNS.
2018-01-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.